Login
Companies $ARDX
$3.09 +$0.02 (0.65%) After hours
ARDELYX, INC. logo

ARDELYX, INC.

ardelyx.com

What Do They Do?

Sells IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for adults with chronic kidney disease on dialysis, and develops other medicines.

How Do They Make Money?

Ardelyx mainly sells medicines to wholesalers, group purchasing organizations and specialty pharmacies, and product sales are counted when buyers receive the products. Collaboration partners pay license fees upfront, milestone amounts when development or regulatory events occur, royalties on sales, and fees for supplied product.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product sales, net
Sold outright

93%
FY2022: 30%
Product supply revenue
Sold outright
3.9%
FY2022: 2.9%
Licensing revenue
Licensed
1.3%
FY2022: 67%
Non-cash royalty revenue related to the sale of future royalties
2.1%
FY2022: 0.0%

Who Are Their Customers?

Most medicine sales go to wholesalers, group purchasing organizations and specialty pharmacies; some go directly to retailers, hospitals, clinics and government agencies. Outside the U.S., Ardelyx works with territory partners that develop and commercialize tenapanor.

Do Revenues Turn Into Profits?

No. It lost $61.6M in FY2025.

Operating income, FY2025
−10% of revenue
▼ −47% (Loss) vs FY2024 (−$28M, −8%)
Net income, FY2025
−15% of revenue
▼ −57% (Loss) vs FY2024 (−$39.1M, −12%)
Free cash flow, FY2025
−11% of revenue
▲ +4% (Loss) vs FY2024 (−$45.8M, −14%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +16%
vs $110.3M in Q3 FY2025
Net income
▲ +24% (Loss)
vs −$969K in Q3 FY2025
Product sales, net share of revenue vs 95.6% in Q3 FY2025

Growing. Revenue grew 40.3x in 4 years, from $10.1M in FY2021 to $407.3M in FY2025, about 152% a year.

XPHOZAH moved into commercial sales The older report described XPHOZAH as a medicine in development for kidney patients on dialysis; the latest report says it is approved and marketed for that use.

Revenue over time
Product sales, net Product supply revenue Licensing revenue Non-cash royalty revenue related to the sale of future royalties Collaborative development revenue
$500M$250M$0

Who Do They Compete With?

Competes with Alebund Pharmaceutical (Hong Kong), Vidasym, Taisho Pharmaceutical, and Unicycive Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support